In a study of people with type 2 diabetes and high cardiovascular risk, those taking semaglutide had a significantly lower risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death
For patients with existing heart conditions, the decision to use these medications requires careful consideration of both potential benefits and risks
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
However, with the increased survival of extremely premature infants, cases of MRI without CF are becoming more common, particularly in regions like East Asia where CF prevalence is low 113,114
Premium Unlimited photo uploads, extra montage styles, larger widgets, and Apple Watch support
lactis is a reasonable addition to try
